Time to put drug giants on trial – Scotsman (UK) Fri, 20 Jun 2003 The UK media-including BBC, the Guardian, the Scotsman, the London Times, and others–have been informing the British public about the hidden health hazards underlying the industry-controlled drug approval and drug marketing process. Current practices have led…
Analysis of paroxetine Yellow Card adverse drug reaction reports (Seroxat/Paxil) Thu, 20 Nov 2003 A unique analysis of the British Yellow Card Reporting system for adverse drug reactions (ADR) found that the nature, the scope and severity of ADRs relating to drug dependency and suicidal behavior from the antidepressant paroxetine…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a…
September 16 2002 Note: Paroxetine Hydrochloride is also known as Seroxat or Paxil 800 hooked on drug seek legal action Patients say warning on side effects inadequate The Guardian Sarah Boseley, health editor More than 800 men and women who have found themselves hooked on the antidepressant Seroxat are seeking…
Risks: Drugs / Vaccines / Trials / Treatment Evidence of antidepressant harm Oct 14, 2005: Andrew Finkelstein Letter to Dr. Russell Katz, Director, Neuropharmacological Drug Products, FDA about FDA’s Failure to Warn about Neurontin-Suicides Aug 29: FDA Response to Utah Court Must Be Truthful Re: Zoloft / SSRI Suicidal Risks…
Unreported Paxil suicides: company abandons “No Addiction” claim Sat, 10 May 2003 GlaxoSmithKline, Britain’s biggest pharmaceutical company will change the label in the UK to reflect the severe withdrawal that its antidepressant drug, Seroxat (Paxil in US) generates in many patients. In Britain, the package label will no longer claim…
The UK adverse event drug reporting system utilizes the Yellow Card system for filing reports.
VIOXX – Merck–MEDCO – a case study Wed, 13 Oct 2004 Vioxx: A case study in how a lethal drug is marketed and dispensed – without MINIMAL safeguards to protect people’s lives. Merck marketed and sold billions of dollars worth of Vioxx through MEDCO–the largest Medicare Pharmacy Benefit Manager (PBM)…
Infomail Archive 2003 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 19, 2003: Eli Lilly Prozac UK Fact Sheet: “Not Recommended” for Children – PMDD Withdrawn in UK Dec 19, 2003: Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Dec 18, 2003:…
